DOI: https://dx.doi.org/10.18203/issn.2454-5929.ijohns20220478
Published: 2022-02-24

Experiences with mucormycosis during COVID times in a government hospital in Kerala-a case series

Sarada Sreenath, Anil Kumar Arupathuparayil Ravi

Abstract


Mucormycosis is a rare invasive fungal infection which is often fatal. At the time of COVID-19 pandemic, there has been a sudden increase in the number of reported cases of mucormycosis. In this case series 10 cases of mucormycosis presented in our hospital during the COVID season are discussed. Of the 10 cases, only 8 patients had history of COVID infection. The predominant comorbidity was diabetes which was detected in all except one patient. But with timely diagnosis and appropriate management majority of the patients survived. Lesser symptoms and better prognosis were observed in patients without previous history of COVID.

 


Keywords


Mucormycosis, COVID, Fungal infection

Full Text:

PDF

References


Al-Tawfiq JA, Alhumaid S, Alshukairi AN, Temsah MH, Barry M, Al Mutair A, et al. COVID-19 and mucormycosis superinfection: the perfect storm. Infection. 2021;49(5):833-53.

Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi. 2020;6:265.

Mohammadi F, Badri M, Safari S, Hemmat N. A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update. BMC Infect Dis. 2021;21:906.

Revannavar SM, Supriya PS, Samaga L, Vineeth VK. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep. 2021;14:e241663.

Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids—an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;20(3):1-8.

Spellberg B, Edwards J, Ibrahim A. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management Clinical microbiology reviews. 2005;18(3):556-69.

Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin N Am. 2000;33(2):349-65.

Directorate General of Health Services. Guideline for management of Mucormycosis in COVID – 19 patient. 2021. Available at: https://dghs.gov.in. Accessed on 15 October 2021.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):405-21.

Michael RC, Michael JS, Ashbee RH, Mathews MS. Mycological profile of fungal sinusitis: An audit of specimens over a 7-year period in a tertiary care hospital in Tamil Nadu. Indian J Pathol Microbiol. 2008;51:493-6.

Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69:244-52.

Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135(5):442-7.

Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol. 2021;69:1563-8.

Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D’Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003;51:231-3.

Jiang N, Zhao G, Yang S, Lin J, Hu L, Che C, Wang Q, Xu Q. A retrospective analysis of eleven cases of invasive rhino-orbito-cerebral mucormycosis presented with orbital apex syndrome initially. BMC Ophthalmol. 2016;16:10.

Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E, Siano M, Mariani U. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. Int J Infect Dis. 2011;15(8):533-40.